Correvio Pharma Corp. is exploring options including putting itself up for sale, a day after a panel of experts advising the U.S. health regulator voted against approving the company’s heart drug.

U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp.’s Brinavess said they did not believe the benefits of the heart drug outweighed the therapy’s risks, sending the company’s shares down nearly 38 percent.

Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.